Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Price: $8.83 +1.26%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ: RNAC) with a Outperform rating and a price target of $39.00.
For an analyst ratings summary and ratings history on Cartesian Therapeutics click here. For more ratings news on Cartesian Therapeutics click here.
Shares of Cartesian Therapeutics closed at $18.26 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
